- Home
- PANW vs LLY Comparison
PANW vs LLY Comparison
Compare PANW & LLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$301.85
HOLD
Current Price
$1,210.96
Company Overview
Basic Information| Metric | PANW | LLY |
|---|---|---|
| Founded | 2005 | 1876 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.5B | 979.6B |
| IPO Year | 2012 | 2007 |
Fundamental Metrics
Financial Performance| Metric | PANW | LLY |
|---|---|---|
| Price | $301.85 | $1,210.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 39 | 19 |
| Target Price | $216.28 | ★ $1,218.84 |
| AVG Volume (30 Days) | ★ 8.0M | 2.4M |
| Earning Date | 05-19-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.81% |
| EPS Growth | N/A | ★ 95.99 |
| EPS | 0.79 | ★ 8.26 |
| Revenue | $2,273,100,000.00 | ★ $65,179,000,000.00 |
| Revenue This Year | $24.93 | $27.15 |
| Revenue Next Year | $19.97 | $16.04 |
| P/E Ratio | $370.17 | ★ $136.56 |
| Revenue Growth | 29.04 | ★ 44.70 |
| 52 Week Low | $139.57 | $623.78 |
| 52 Week High | $302.95 | $1,182.73 |
Technical Indicators
Market Signals| Indicator | PANW | LLY |
|---|---|---|
| Relative Strength Index (RSI) | 69.57 | 72.82 |
| Support Level | $179.81 | $1,032.70 |
| Resistance Level | $302.95 | N/A |
| Average True Range (ATR) | 11.33 | 37.16 |
| MACD | -0.85 | -0.76 |
| Stochastic Oscillator | 99.51 | 97.11 |
Price Performance
Historical Comparison PANW
LLY
About PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three-fourths of the Global 2000.
About LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.